Conflict Of Interest Reform Fight Reignites Following Panel Revelations
This article was originally published in The Tan Sheet
Advisory committee conflict of interest reform draws increased attention in the wake of concerns raised about a recent Reproductive Health panel meeting.
You may also be interested in...
Adjusting advisory committee conflict of interest rules becomes a high-priority issue in reauthorizing FDA’s drug user fee program. With several bills proposing to loosen the rules, Sen. Hagan’s draft FDA reform legislation could bring the most changes.
Only about one-third of biosimilars received a first-cycle approval from US FDA after product quality discussions during the mid-assessment-cycle meeting, according to an interim report on the biosimilar application review program.
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.